TNF-beta Inhibitors & Biosimilars
1 drugsAbout TNF-beta
Tumor Necrosis Factor-beta (TNF-beta), also known as lymphotoxin-alpha (LT-α), is a cytokine that mediates communication between cells, particularly within the immune system. It plays a crucial role in lymphoid organ development and in regulating immune responses.
TNF-beta's involvement in inflammatory pathways makes it a relevant target for therapeutic intervention. Currently, there is no genetic evidence data available linking TNF-beta to specific diseases in this dataset.
TNF-beta is targeted by one FDA-approved drug, ENBREL, a fusion protein developed by IMMUNEX. ENBREL has 6 indications and was first approved in 1998.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Tinnitus, Noise Induced with only 1 trials.
Top TNF-beta Drugs
IMMUNEX is the only company with an approved drug targeting TNF-beta.
The market is highly concentrated, indicating potential entry barriers or limited commercial opportunity.
TNF-beta Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TNF-beta, using fusion protein modality.
Explore alternative modalities like antibodies or small molecules to differentiate from existing therapies.
TNF-beta Clinical Trials 139 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 24 | 16 | 6 | 2 | 73% |
| Phase 2 | 20 | 13 | 3 | 4 | 81% |
| Phase 3 | 41 | 34 | 3 | 3 | 92% |
| Phase 4 | 54 | 36 | 15 | 3 | 71% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TNF-beta Drug Approval Timeline (1998 - 1998)
The first and only drug, ENBREL, was approved in 1998.
The approval timeline suggests market saturation; consider novel approaches to revitalize the target.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 55 clinical trials targeting TNF-beta.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities